|
Revenue from operations increased marginally to Rs 881.84 crore in Q4 FY23 as against Rs 870.29 crore recorded in same quarter last year.
Profit before tax declined 23% to Rs 152.05 crore in Q4 FY23 as compared with Rs 197.67 crore in Q4 FY22.
EBITDA stood at Rs 149 crore in Q4 FY23, down 17% as against Rs 207 crore posted in corresponding quarter last year.
During the quarter, total branded generic sales was down 3% to Rs 625 crore as compared with Rs 644 crore posted in Q4 FY22.
In quarter ended 31 March 2023, revenue from India stood at Rs 287 crore (up 17% YoY ) while revenue from Africa stood at Rs 100 crore (down 26% YoY), revenue from Asia was at Rs 238 crore (down 9% YoY) and revenue from US stood at Rs 197 crore (up 17% YoY).
During Q4 FY23, R&D expenses were Rs 63 crore, which is 7% of revenue from operations. R&D expenses were Rs 59 crore in Q4 FY22.
On full year basis, the company's net profit declined 17.5% to Rs 587.98 crore despite of 12% jump in revenue from operations to Rs 3,742.64 crore in FY23 over FY22.
Ajanta Pharma is a specialty pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa.
|